Michael W. Jann
Mercer University College of Pharmacy and Health Sciences
3001 Mercer University Dr.
Atlanta
GA, 30341
USA
Name/email consistency: high
- Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir. Jann, M.W., Spratlin, V., Momary, K., Zhang, H., Turner, D., Penzak, S.R., Wright, A., Vandenberg, C. Eur. J. Clin. Pharmacol. (2012)
- Antidepressant agents for the treatment of chronic pain and depression. Jann, M.W., Slade, J.H. Pharmacotherapy (2007)
- Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis. Jann, M.W. Pharmacotherapy (2004)
- Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Jann, M.W., Shirley, K.L., Small, G.W. Clin. Pharmacokinet (2002)
- Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype. Jan, M.W., ZumBrunnen, T.L., Kazmi, Y.R., VanDenBerg, C.M., Desai, H.D., Weidler, D.J., Flockhart, D.A. Drug. Metabol. Drug. Interact (2002)
- Clinical significance of drug binding, protein binding, and binding displacement drug interactions. Jann, M.W. Psychopharmacol. Bull (2002)
- Pharmacology and clinical efficacy of cholinesterase inhibitors. Jann, M.W. Am. J. Health. Syst. Pharm (1998)